DK1501499T3 - Transepikutan indgivelsesform til behandling af restless legs-syndromet - Google Patents

Transepikutan indgivelsesform til behandling af restless legs-syndromet

Info

Publication number
DK1501499T3
DK1501499T3 DK03727432T DK03727432T DK1501499T3 DK 1501499 T3 DK1501499 T3 DK 1501499T3 DK 03727432 T DK03727432 T DK 03727432T DK 03727432 T DK03727432 T DK 03727432T DK 1501499 T3 DK1501499 T3 DK 1501499T3
Authority
DK
Denmark
Prior art keywords
restless leg
leg syndrome
treatment
administration
transepicutaneous
Prior art date
Application number
DK03727432T
Other languages
Danish (da)
English (en)
Inventor
Erwin Schollmayer
Thomas Lauterbach
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29285132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1501499(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of DK1501499T3 publication Critical patent/DK1501499T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03727432T 2002-05-06 2003-05-05 Transepikutan indgivelsesform til behandling af restless legs-syndromet DK1501499T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10220230A DE10220230A1 (de) 2002-05-06 2002-05-06 Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
PCT/EP2003/004685 WO2003092677A1 (de) 2002-05-06 2003-05-05 Transepikutane darreichungsform zur behandlung des restless leg syndroms

Publications (1)

Publication Number Publication Date
DK1501499T3 true DK1501499T3 (da) 2008-06-23

Family

ID=29285132

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03727432T DK1501499T3 (da) 2002-05-06 2003-05-05 Transepikutan indgivelsesform til behandling af restless legs-syndromet

Country Status (23)

Country Link
EP (1) EP1501499B1 (https=)
JP (2) JP5253707B2 (https=)
KR (1) KR20040104697A (https=)
CN (1) CN100396281C (https=)
AT (1) ATE387912T1 (https=)
AU (1) AU2003233233B2 (https=)
BR (1) BR0309837A (https=)
CA (2) CA2483120C (https=)
CY (1) CY1107452T1 (https=)
DE (2) DE10220230A1 (https=)
DK (1) DK1501499T3 (https=)
ES (1) ES2301795T3 (https=)
IL (2) IL164861A0 (https=)
MX (1) MXPA04010687A (https=)
NO (1) NO333619B1 (https=)
NZ (1) NZ536533A (https=)
PL (1) PL218549B1 (https=)
PT (1) PT1501499E (https=)
RU (1) RU2301063C9 (https=)
SI (1) SI1501499T1 (https=)
UA (1) UA81625C2 (https=)
WO (1) WO2003092677A1 (https=)
ZA (1) ZA200408862B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
MY149152A (en) 2006-05-08 2013-07-15 Teikoku Seiyaku Kk Percutaneous absorption preparations of antimentia drugs
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
NZ584363A (en) 2007-11-28 2012-11-30 Ucb Pharma Gmbh Drug formulations of Rotigotine which comprise the thermodynamically stable polymorphic form 2
US9155725B2 (en) 2008-02-27 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
EP2255809B1 (en) * 2008-02-27 2017-08-23 Hisamitsu Pharmaceutical Co., Inc. Medicated patch
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
LT3257504T (lt) 2009-12-22 2024-08-26 UCB Biopharma SRL Polivinilpirolidonas, skirtas nekristalinės formos kietos rotigotino dispersijos stabilizavimui
US8729306B2 (en) 2010-02-05 2014-05-20 Ucb Pharma Gmbh Process for the preparation of nitrogen substituted aminotetralins derivatives
BR112012029944A2 (pt) 2010-06-25 2019-09-24 Ucb Pharma Gmbh processo para preparação de derivados de aminotetralinas substituídas com nitrogênio
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
MX2015000049A (es) * 2012-07-05 2015-04-08 Sk Chemicals Co Ltd Preparacion absorbible transdermicamente que contiene rotigotina.
EP2870963A4 (en) * 2012-07-06 2016-03-09 Sk Chemicals Co Ltd PREPARATION CONTAINING ROTIGOTINE FOR PERCUTANEOUS ABSORBING
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP6726096B2 (ja) 2013-07-03 2020-07-22 エルテーエス ローマン テラピー−システメ アーゲー 電子部品を有する経皮治療システム
WO2015129527A1 (ja) 2014-02-27 2015-09-03 株式会社メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
CN106456566B (zh) 2014-05-20 2020-06-16 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
JP6872675B1 (ja) 2019-06-14 2021-05-19 久光製薬株式会社 ロチゴチン含有貼付剤
ES2966170T3 (es) 2020-01-24 2024-04-18 Luye Pharma Switzerland Ag Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
DE4238223C1 (de) * 1992-11-12 1994-05-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung
US5482988A (en) * 1994-01-14 1996-01-09 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive with siloxylated polyether waxes as additives
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
ATE246919T1 (de) * 2001-05-08 2003-08-15 Sanol Arznei Schwarz Gmbh Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
EP1256339B1 (en) * 2001-05-08 2003-10-15 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine

Also Published As

Publication number Publication date
IL164861A0 (en) 2005-12-18
PL373276A1 (en) 2005-08-22
AU2003233233B2 (en) 2008-03-06
CY1107452T1 (el) 2012-12-19
KR20040104697A (ko) 2004-12-10
CA2787384A1 (en) 2003-11-13
AU2003233233A1 (en) 2003-11-17
CN100396281C (zh) 2008-06-25
ES2301795T3 (es) 2008-07-01
CA2483120A1 (en) 2003-11-13
DE50309318D1 (de) 2008-04-17
RU2004131866A (ru) 2005-06-10
PL218549B1 (pl) 2014-12-31
JP5253707B2 (ja) 2013-07-31
PT1501499E (pt) 2008-05-20
UA81625C2 (ru) 2008-01-25
IL164861A (en) 2011-06-30
CA2483120C (en) 2013-07-16
MXPA04010687A (es) 2005-06-08
ATE387912T1 (de) 2008-03-15
JP2005528413A (ja) 2005-09-22
RU2301063C2 (ru) 2007-06-20
JP2010159302A (ja) 2010-07-22
CN1665497A (zh) 2005-09-07
HK1072541A1 (zh) 2005-09-02
ZA200408862B (en) 2005-09-28
SI1501499T1 (sl) 2008-06-30
NO333619B1 (no) 2013-07-22
EP1501499B1 (de) 2008-03-05
WO2003092677A1 (de) 2003-11-13
RU2301063C9 (ru) 2007-11-27
NO20045240L (no) 2004-11-30
BR0309837A (pt) 2005-03-01
DE10220230A1 (de) 2003-11-27
NZ536533A (en) 2010-02-26
EP1501499A1 (de) 2005-02-02

Similar Documents

Publication Publication Date Title
CY1107452T1 (el) Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων
SG146643A1 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
DK1587506T3 (da) Administration af capsaicinoider
NO20024586L (no) FremgangsmÕte og preparat for prevensjon av hormoninduserte ugunstige virkninger
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
MY169275A (en) Method of immunization against the four serotypes of dengue
DK1363608T3 (da) Formuleringer omfattende ibuprofen og diphenhydramin og deres anvendelse til behandling af sovnforstyrrelser
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
RU2003133217A (ru) Чрескожная терапевтическая система для лечения болезни паркинсона, индуцирующая высокие уровни ротиготина в плазме
TW200517107A (en) Novel formulation
WO2004012655A3 (en) Anti-microbial compositions and methods of using same
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
DK1154795T3 (da) Middel til behandling af diagnosticering af restless legs syndrom
DE602005024571D1 (de) Opioide zur behandlung von ruhelosigkeit in den unteren gliedmassen
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
DE60236443D1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
TW200618807A (en) Prevention and therapeutical agent for hepatitis C virus infection
SE0203817D0 (sv) New composition
ATE370733T1 (de) Pharmazeutische kombinationspräparat zur behandlung von spastischkeit und/oder schmerzen